Virtus Investment Advisers, Inc. Arcus Biosciences, Inc. Transaction History
Virtus Investment Advisers, Inc.
- $289 Million
- Q1 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 9,572 shares of RCUS stock, worth $94,284. This represents 0.03% of its overall portfolio holdings.
Number of Shares
9,572Holding current value
$94,284% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
63.1MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$96.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$65.9 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$50.5 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$36.4 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$28.2 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $711M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...